Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older
By Dr. Matthew Watson
COPENHAGEN, Denmark, February 28, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced that the European Commission has granted marketing authorization in Europe for VIMKUNYA® for active immunization for the prevention of disease caused by chikungunya virus in individuals 12 years and older.
Read the original:
Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older
Related Post
- TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis - March 1st, 2025
- AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza - March 1st, 2025
- Ultimovacs ASA: Approval and publication of prospectus - March 1st, 2025
- Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous... - March 1st, 2025
- Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting - March 1st, 2025
- InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - March 1st, 2025
- Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting... - March 1st, 2025
- CORRECTION: Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call - March 1st, 2025
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - March 1st, 2025
- ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting - March 1st, 2025
- SRx Health Solutions Granted Final Order to Proceed with the Acquisition by Better Choice Company - March 1st, 2025
- Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ® - March 1st, 2025
- Orion Corporation: Managers’ transactions – Outi Vaarala - March 1st, 2025
- Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination... - March 1st, 2025
- Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy - March 1st, 2025
- Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - March 1st, 2025
- 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - March 1st, 2025
- Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update - March 1st, 2025
- Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - March 1st, 2025
- Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference - February 20th, 2025
- NAYA Biosciences Announces Nomination of New Board Members - February 20th, 2025
- Intrommune Therapeutics Announces Publication of OMEGA Study in Peanut Allergic Adults in Annals of Allergy, Asthma & Immunology - February 20th, 2025
- OrphAI Therapeutics Announces Appointment of Dr. Aaron Waxman to Board of Directors - February 20th, 2025
- Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate - February 20th, 2025
- Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers - February 20th, 2025
- NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock - February 20th, 2025
- Better Choice Company Adjourns Special Meeting of Stockholders to March 21, 2025 - February 20th, 2025
- COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing - February 20th, 2025
- Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025 - February 20th, 2025
- GRI Bio Announces Reverse Stock Split - February 20th, 2025
- PacBio to Participate in TD Cowen's 45th Annual Health Care Conference - February 20th, 2025
- ANI Pharmaceuticals to Present at Raymond James’ Institutional Investors and Leerink Partners Global Healthcare Conferences in March - February 20th, 2025
- Intelligent Bio Solutions Inc. Announces Proposed Public Offering of Common Stock - February 20th, 2025
- Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 - February 20th, 2025
- Zealand Pharma Announces Financial Results for the Full Year 2024 - February 20th, 2025
- argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025 - February 20th, 2025
- EG 427 raises €27 million in successful Series B co-led by Andera Partners and Bpifrance to finance on-going clinical study and platform... - February 20th, 2025
- Apellis and Sobi Announce EMA Validation of Indication Extension Application for Aspaveli® (pegcetacoplan) for C3G and Primary IC-MPGN - February 20th, 2025
- Citryll Demonstrates a Broader Therapeutic Potential for CIT-013 in the Treatment of Inflammatory Disorders - February 20th, 2025
- Grace Therapeutics Announces Private Placement Financing of up to $30 Million - February 11th, 2025
- IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer - February 11th, 2025
- Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience - February 11th, 2025
- Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis - February 11th, 2025
- Intelligent Bio Solutions Releases Shareholder Letter Detailing 2024 Growth and 2025 U.S. Expansion Strategy - February 11th, 2025
- Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial - February 11th, 2025
- BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology /... - February 11th, 2025
- Capricor Therapeutics to Participate in Upcoming Investor Conferences - February 11th, 2025
- Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - February 11th, 2025
- Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting - February 11th, 2025
- Immix Biopharma Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201, sterically-optimized CAR-T for relapsed/refractory... - February 11th, 2025
- Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol - February 11th, 2025
- Revolo to Present at the 2025 AAAAI / WAO Joint Congress - February 11th, 2025
- Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update - February 11th, 2025
- Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update - February 11th, 2025
- Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - February 11th, 2025
- Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation - February 11th, 2025
- LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement - February 11th, 2025
- Novonesis to acquire dsm-firmenich’s share of the Feed Enzyme Alliance - February 11th, 2025
- Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront - February 11th, 2025
- Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange - January 31st, 2025
- Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - January 31st, 2025
- PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025 - January 31st, 2025
- Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - January 31st, 2025
- Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference - January 31st, 2025
- Avid Stockholders Approve Transaction with GHO and Ampersand - January 31st, 2025
- Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025 - January 31st, 2025
- Portage Biotech Announces Completion of $2.15 Million Private Financing - January 31st, 2025
- Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision... - January 31st, 2025
- Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI - January 31st, 2025
- Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics - January 31st, 2025
- Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine - January 31st, 2025
- Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - January 31st, 2025
- BioSyent Declares First Quarter 2025 Dividend - January 31st, 2025
- Tarsus to Participate in Upcoming Investor Conferences - January 31st, 2025
- Ryoncil® Commercial Launch Update and Product Pipeline - January 31st, 2025
- Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 - January 31st, 2025
- Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 - January 31st, 2025
- Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for... - January 31st, 2025
- Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update - January 31st, 2025
- Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - January 22nd, 2025
Global News Feed
Comments Off on Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older |
March 1st, 2025
This author published 6072 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research